Pacira BioSciences (PCRX) Financials

$24.88 -0.09 (-0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$24.88 0.00 (0.00%)

As of 05:08 PM Eastern

Annual Income Statements for Pacira BioSciences

This table shows Pacira BioSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-14	1.86	-38	-43	-0.47	-11	146	42	-15	9.34	-404
Consolidated Net Income / (Loss)	-14	1.86	-38	-43	-0.47	-11	146	42	32	84	-199
Net Income / (Loss) Continuing Operations	-14	1.86	-38	-43	-0.47	-11	146	42	-15	9.34	-404
Total Pre-Tax Income	-14	2.12	-38	-42	-0.43	-11	20	56	27	123	-126
Total Operating Income	-5.17	9.46	-32	-25	16	10	46	90	60	88	-73
Total Gross Profit	120	177	166	199	250	314	312	401	1,134	1,165	1,232
Total Revenue	198	249	276	287	337	421	430	542	1,334	1,350	1,402
Operating Revenue	198	249	276	287	337	421	430	542	1,334	1,350	1,402
Total Cost of Revenue	77	72	110	88	87	107	117	140	199	185	170
Operating Cost of Revenue	77	72	110	88	87	107	117	140	199	185	170
Total Operating Expenses	125	168	198	224	235	304	266	311	1,061	1,048	1,591
Selling, General & Admin Expense	107	139	153	161	177	201	194	199	255	269	294
Research & Development Expense	19	29	46	57	56	72	59	56	85	76	82
Amortization Expense	-	-	-	0.00	0.00	5.70	7.87	14	115	115	115
Other Operating Expenses / (Income)	-	0.00	0.00	-	-	-	-	43	607	587	774
Impairment Charge	-	-	-	-	-	-	5.17	-	0.00	0.00	326
Total Other Income / (Expense), net	-8.38	-7.34	-5.82	-18	-16	-21	-26	-34	-93	-69	28
Interest Expense	8.28	7.78	7.06	22	22	24	34	32	40	54	1.53
Interest & Investment Income	0.38	0.68	1.32	4.08	6.50	7.38	4.63	0.90	4.54	11	20
Other Income / (Expense), net	-0.48	-0.24	-0.08	0.17	-0.89	-4.98	2.85	-2.67	-58	-26	9.89
Income Tax Expense	0.17	0.26	0.11	0.14	0.05	0.27	-125	14	-5.21	39	73
Basic Earnings per Share	($0.39)	$0.05	($1.02)	($1.07)	($0.01)	($0.27)	$3.41	$0.95	$0.35	$0.91	($2.15)
Weighted Average Basic Shares Outstanding	35.30M	36.54M	37.24M	39.81M	40.91M	41.51M	42.67M	44.26M	45.52M	46.22M	46.25M
Diluted Earnings per Share	($0.39)	$0.04	($1.02)	($1.07)	($0.01)	($0.27)	$3.33	$0.92	$0.34	$0.89	($2.15)
Weighted Average Diluted Shares Outstanding	35.30M	41.30M	37.24M	39.81M	40.91M	41.51M	43.68M	45.63M	46.54M	51.98M	46.25M
Weighted Average Basic & Diluted Shares Outstanding	35.30M	37.10M	37.24M	39.81M	40.91M	41.51M	43.86M	44.85M	45.95M	46.50M	46.28M

This table shows Pacira BioSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-0.69	-41	-20	26	11	-7.74	8.98	19	-143	-289
Consolidated Net Income / (Loss)	-0.69	5.81	-20	26	11	67	8.98	19	-143	-84
Net Income / (Loss) Continuing Operations	-0.69	-41	-20	26	11	-7.74	8.98	19	-143	-289
Total Pre-Tax Income	2.07	-4.77	-26	38	17	95	14	37	-139	-38
Total Operating Income	21	-9.89	-3.09	40	18	33	13	28	-140	25
Total Gross Profit	117	777	111	121	124	809	120	134	130	848
Total Revenue	167	839	160	169	164	856	167	178	169	888
Operating Revenue	167	839	160	169	164	856	167	178	169	888
Total Cost of Revenue	51	62	49	48	40	48	47	44	39	40
Operating Cost of Revenue	51	62	49	48	40	48	47	44	39	40
Total Operating Expenses	95	773	114	81	106	745	106	106	269	1,110
Selling, General & Admin Expense	61	64	71	65	68	66	72	68	74	80
Research & Development Expense	19	18	17	19	21	19	18	20	19	24
Amortization Expense	14	72	14	14	14	72	14	14	14	72
Total Other Income / (Expense), net	-19	-55	-23	-2.02	-1.12	-42	0.43	8.34	0.67	19
Interest Expense	9.86	11	27	3.87	3.46	20	3.32	-3.63	4.69	-2.84
Interest & Investment Income	1.23	2.79	3.14	2.11	2.77	3.43	3.90	4.75	5.48	5.56
Other Income / (Expense), net	-11	-47	-0.01	-0.27	-0.42	-25	-0.16	-0.04	-0.12	10
Income Tax Expense	2.76	-11	-6.94	12	5.74	29	4.66	18	4.61	46
Basic Earnings per Share	($0.02)	($0.22)	($0.43)	$0.56	$0.23	$0.55	$0.19	$0.41	($3.11)	$0.36
Weighted Average Basic Shares Outstanding	45.83M	45.52M	45.95M	46.09M	46.42M	46.22M	46.50M	46.17M	46.13M	46.25M
Diluted Earnings per Share	($0.02)	($0.19)	($0.43)	$0.51	$0.23	$0.58	$0.19	$0.39	($3.11)	$0.38
Weighted Average Diluted Shares Outstanding	45.83M	46.54M	45.95M	52.05M	52.07M	51.98M	52.19M	50.54M	46.13M	46.25M
Weighted Average Basic & Diluted Shares Outstanding	-	45.95M	45.99M	46.42M	46.44M	46.50M	46.55M	46.13M	46.17M	46.28M

This table details how cash moves in and out of Pacira BioSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	25	19	-21	18	78	-54	22	486	-481	49	123
Net Cash From Operating Activities	27	28	33	18	49	71	77	126	145	155	189
Net Cash From Continuing Operating Activities	27	28	33	18	49	71	77	126	145	155	189
Net Income / (Loss) Continuing Operations	-14	1.86	-38	-43	-0.47	-11	146	42	16	42	-100
Consolidated Net Income / (Loss)	-14	1.86	-38	-43	-0.47	-11	146	42	16	42	-100
Depreciation Expense	10	11	13	14	13	20	20	29	92	76	79
Amortization Expense	4.63	4.58	4.57	12	13	15	18	26	7.21	3.75	3.22
Non-Cash Adjustments To Reconcile Net Income	25	33	32	37	34	39	41	45	85	67	209
Changes in Operating Assets and Liabilities, net	0.64	-23	22	-2.57	-11	7.90	-147	-16	-54	-34	-2.36
Net Cash From Investing Activities	-120	-19	-62	-224	21	-128	-278	-21	-225	78	-83
Net Cash From Continuing Investing Activities	-120	-19	-62	-224	21	-128	-278	-21	-225	78	-83
Purchase of Property, Plant & Equipment	-23	-40	-25	-19	-15	-10	-38	-46	-30	-15	-11
Purchase of Investments	-164	-189	-193	-503	-363	-320	-548	-629	-401	-144	-252
Sale and/or Maturity of Investments	80	217	172	322	405	319	308	1,078	238	237	180
Other Investing Activities, net	-13	-7.12	-16	-8.46	-6.84	0.00	0.00	-4.00	-32	0.00	0.00
Net Cash From Financing Activities	119	11	7.26	224	8.95	3.67	222	381	-402	-183	17
Net Cash From Continuing Financing Activities	119	11	7.26	224	8.95	3.67	222	381	-402	-183	17
Repayment of Debt	0.00	-1.47	0.00	-129	0.00	-0.34	-189	0.00	-428	-336	-211
Repurchase of Common Equity	-	-	-	-	-	-	-	-4.55	-1.18	-1.16	-34
Issuance of Debt	0.00	0.00	0.00	345	0.00	0.00	369	364	0.00	150	288
Issuance of Common Equity	112	2.09	1.50	1.86	1.78	2.40	2.55	2.81	2.95	2.81	2.30
Other Financing Activities, net	7.24	10	5.77	6.49	7.17	1.61	40	19	24	1.83	-27
Cash Interest Paid	5.19	4.22	3.85	6.90	8.21	8.20	7.21	7.00	33	28	15
Cash Income Taxes Paid	0.03	0.20	0.25	0.13	0.13	0.86	2.42	3.22	7.40	4.37	11

This table details how cash moves in and out of Pacira BioSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-13	-5.29	-69	51	12	54	31	63	-1.09	31
Net Cash From Operating Activities	43	42	19	43	44	48	49	53	54	33
Net Cash From Continuing Operating Activities	43	42	19	43	44	48	49	53	54	33
Net Income / (Loss) Continuing Operations	-0.69	-10	-20	26	11	25	8.98	19	-143	16
Consolidated Net Income / (Loss)	-0.69	-10	-20	26	11	25	8.98	19	-143	16
Depreciation Expense	20	30	20	19	18	18	18	19	20	21
Amortization Expense	1.60	2.14	1.61	0.72	0.71	0.71	0.71	0.79	0.86	0.87
Non-Cash Adjustments To Reconcile Net Income	23	39	29	11	15	12	13	5.04	176	15
Changes in Operating Assets and Liabilities, net	-1.21	-19	-11	-13	-0.50	-8.62	7.77	9.66	-0.04	-20
Net Cash From Investing Activities	-48	11	66	7.33	-4.34	8.37	-16	-15	-52	-0.37
Net Cash From Continuing Investing Activities	-48	11	66	7.33	-4.34	8.37	-16	-15	-52	-0.37
Purchase of Property, Plant & Equipment	-5.18	-5.49	-6.57	-3.40	-3.39	-1.80	-2.84	-1.59	-4.09	-2.12
Purchase of Investments	-132	-68	-53	-23	-42	-26	-56	-50	-101	-45
Sale and/or Maturity of Investments	90	85	126	34	41	36	43	36	53	47
Net Cash From Financing Activities	-7.78	-59	-154	0.44	-28	-1.78	-2.82	25	-2.85	-1.96
Net Cash From Continuing Financing Activities	-7.78	-59	-154	0.44	-28	-1.78	-2.82	25	-2.85	-1.96
Repayment of Debt	-9.38	-59	-303	-2.81	-28	-2.81	-2.81	-202	-2.81	-2.81
Issuance of Common Equity	-0.00	1.13	-	-	-0.00	1.14	-	-	-	0.93
Other Financing Activities, net	1.60	0.91	0.33	1.58	0.03	-0.11	-0.00	-27	-0.03	-0.08
Cash Interest Paid	8.93	9.68	18	3.17	4.13	2.70	3.97	3.02	3.20	5.23
Cash Income Taxes Paid	0.11	3.18	0.20	0.59	1.28	2.29	-0.25	4.91	4.91	1.45

This table presents Pacira BioSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	326	388	391	628	689	831	1,275	2,075	1,681	1,574	1,554
Total Current Assets	214	253	243	391	478	409	652	866	498	510	745
Cash & Equivalents	38	57	36	54	133	78	100	586	104	153	277
Short-Term Investments	119	102	137	257	251	214	422	71	185	125	208
Accounts Receivable	22	26	30	32	38	48	53	96	98	106	113
Inventories, net	29	62	31	41	49	58	65	99	96	104	125
Prepaid Expenses	4.46	6.12	9.28	6.69	7.95	11	12	15	15	22	22
Plant, Property, & Equipment, net	61	90	101	107	109	105	137	188	184	174	167
Total Noncurrent Assets	51	45	47	130	103	318	486	1,021	999	890	641
Long-Term Investments	24	13	0.00	74	41	65	95	22	64	38	36
Goodwill	24	31	47	55	62	100	100	145	163	163	0.00
Intangible Assets	0.40	0.08	-	-	0.00	104	97	624	541	483	426
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	0.00	106	153	160	144	130
Other Noncurrent Operating Assets	2.59	0.41	0.62	0.83	0.00	49	89	76	71	61	49
Total Liabilities & Shareholders' Equity	326	388	391	628	689	831	1,275	2,075	1,681	1,574	1,554
Total Liabilities	155	169	172	349	368	476	655	1,345	906	704	775
Total Current Liabilities	140	150	45	56	61	108	253	521	148	97	310
Short-Term Debt	103	104	0.00	0.32	0.34	0.00	150	375	34	8.64	202
Accounts Payable	6.76	8.74	7.51	15	14	13	10	11	15	16	19
Accrued Expenses	28	35	37	41	46	70	71	128	90	64	80
Other Current Liabilities	0.28	-	-	-	0.00	23	22	7.89	9.12	8.80	8.89
Total Noncurrent Liabilities	15	20	128	293	307	368	401	824	758	607	465
Long-Term Debt	-	0.00	109	276	291	306	313	675	656	514	384
Other Noncurrent Operating Liabilities	5.41	11	19	16	17	62	88	149	103	93	82
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	171	218	219	279	321	355	620	730	775	870	778
Total Preferred & Common Equity	171	218	219	279	321	355	620	730	775	870	778
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	171	218	219	279	321	355	620	730	775	870	778
Common Stock	481	527	565	669	710	754	873	942	924	977	1,009
Retained Earnings	-310	-308	-346	-389	-388	-399	-254	-212	-149	-107	-206
Treasury Stock	-	-	-	-	-	-	-	-	-	0.00	-25
Accumulated Other Comprehensive Income / (Loss)	-0.08	-0.05	-0.03	-0.45	-0.28	0.32	0.32	0.17	-0.38	0.25	0.34

This table presents Pacira BioSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,523	1,542	1,534	1,583	1,647	1,522
Total Current Assets	376	429	447	543	632	690
Cash & Equivalents	36	87	99	184	247	246
Short-Term Investments	138	134	136	142	157	208
Accounts Receivable	93	99	97	102	105	101
Inventories, net	93	92	97	97	103	112
Prepaid Expenses	16	17	19	19	20	24
Plant, Property, & Equipment, net	182	180	176	172	169	167
Total Noncurrent Assets	966	933	911	868	846	665
Long-Term Investments	8.28	36	36	37	36	37
Goodwill	163	163	163	163	163	0.00
Intangible Assets	526	512	498	469	455	440
Noncurrent Deferred & Refundable Income Taxes	168	156	152	141	135	134
Other Noncurrent Operating Assets	100	66	63	59	56	54
Total Liabilities & Shareholders' Equity	1,523	1,542	1,534	1,583	1,647	1,522
Total Liabilities	755	734	703	691	768	772
Total Current Liabilities	99	109	94	93	93	306
Short-Term Debt	11	20	8.64	8.64	0.00	201
Accounts Payable	17	24	17	8.98	19	19
Accrued Expenses	62	56	60	67	65	76
Other Current Liabilities	8.95	8.98	8.63	9.00	9.15	9.19
Total Noncurrent Liabilities	657	625	609	598	675	466
Long-Term Debt	543	532	516	512	589	386
Other Noncurrent Operating Liabilities	114	93	93	86	86	80
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	768	808	832	892	879	750
Total Preferred & Common Equity	768	808	832	892	879	750
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	768	808	832	892	879	750
Common Stock	936	951	963	990	983	996
Retained Earnings	-168	-143	-132	-98	-79	-222
Treasury Stock	-	-	-	-	-25	-25
Accumulated Other Comprehensive Income / (Loss)	-0.14	-0.17	-0.01	0.15	0.11	0.68

This table displays calculated financial ratios and metrics derived from Pacira BioSciences' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	131.05%	25.97%	10.99%	3.71%	17.67%	24.83%	2.05%	26.04%	146.27%	1.22%	3.85%
EBITDA Growth	120.58%	180.42%	-157.84%	105.02%	5,484.60%	-1.12%	115.54%	62.21%	-28.92%	39.83%	-86.84%
EBIT Growth	89.53%	263.25%	-448.26%	22.85%	160.67%	-63.37%	793.93%	77.35%	-97.69%	2,954.37%	-203.19%
NOPAT Growth	90.31%	328.95%	-370.81%	22.13%	163.82%	-34.15%	4,476.82%	-80.07%	7.26%	-16.95%	-186.15%
Net Income Growth	78.54%	113.53%	-2,144.67%	-12.28%	98.89%	-2,238.85%	1,421.01%	-71.15%	-24.21%	163.72%	-337.30%
EPS Growth	79.79%	110.26%	-2,650.00%	-4.90%	99.07%	-2,600.00%	1,333.33%	-72.37%	-63.04%	161.76%	-341.57%
Operating Cash Flow Growth	160.60%	5.48%	19.39%	-46.84%	174.78%	44.30%	9.23%	63.20%	15.56%	6.45%	22.46%
Free Cash Flow Firm Growth	47.81%	-73.66%	45.03%	-19.07%	80.33%	-1,588.67%	260.50%	-425.64%	110.82%	55.15%	89.20%
Invested Capital Growth	37.97%	63.68%	3.41%	9.88%	10.32%	61.81%	52.92%	136.70%	0.93%	-3.23%	-21.58%
Revenue Q/Q Growth	16.66%	3.12%	1.31%	2.20%	4.99%	6.94%	2.03%	5.50%	0.00%	102.79%	101.73%
EBITDA Q/Q Growth	190.52%	-24.91%	-11.42%	105.67%	7.00%	-17.14%	26.57%	-4.35%	0.00%	3.05%	28.86%
EBIT Q/Q Growth	76.08%	-48.78%	-5.38%	30.75%	31.61%	-67.21%	59.09%	-14.60%	0.00%	39.83%	1.91%
NOPAT Q/Q Growth	77.45%	-52.05%	-5.43%	30.47%	31.34%	-81.95%	-64.95%	-21.74%	0.00%	89.70%	-13.04%
Net Income Q/Q Growth	56.42%	-81.73%	-4.04%	16.74%	88.68%	-610.71%	15.38%	-31.88%	0.00%	1,101.63%	-119.46%
EPS Q/Q Growth	57.61%	-85.71%	-5.15%	18.94%	88.89%	-640.00%	16.84%	-34.75%	0.00%	641.67%	-10.26%
Operating Cash Flow Q/Q Growth	437.73%	8.82%	1.07%	-2.30%	9.62%	7.11%	36.90%	-15.72%	0.00%	3.72%	-7.09%
Free Cash Flow Firm Q/Q Growth	14.84%	2.28%	14.73%	-19.30%	60.93%	-51.46%	-77.98%	-1,397.82%	-87.85%	109.06%	-6.61%
Invested Capital Q/Q Growth	13.07%	0.30%	-3.40%	4.59%	0.05%	1.26%	0.06%	117.36%	0.00%	-0.91%	-0.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	60.82%	71.15%	60.16%	69.33%	74.25%	74.65%	72.69%	74.10%	85.06%	86.32%	87.84%
EBITDA Margin	4.56%	10.15%	-5.29%	0.26%	12.15%	9.63%	20.33%	26.17%	7.55%	10.43%	1.32%
Operating Margin	-2.61%	3.80%	-11.59%	-8.70%	4.72%	2.49%	10.79%	16.61%	4.50%	6.49%	-5.23%
EBIT Margin	-2.86%	3.70%	-11.62%	-8.64%	4.46%	1.31%	11.45%	16.11%	0.15%	4.56%	-4.53%
Profit (Net Income) Margin	-6.94%	0.75%	-13.73%	-14.87%	-0.14%	-2.62%	33.87%	7.75%	2.39%	6.22%	-14.20%
Tax Burden Percent	101.28%	87.55%	100.28%	100.33%	110.82%	102.49%	724.39%	74.43%	119.60%	68.00%	157.77%
Interest Burden Percent	239.83%	23.00%	117.87%	171.46%	-2.83%	-195.28%	40.83%	64.64%	1,320.95%	200.60%	198.82%
Effective Tax Rate	0.00%	12.45%	0.00%	0.00%	0.00%	0.00%	-624.39%	25.57%	-19.60%	32.00%	0.00%
Return on Invested Capital (ROIC)	-4.57%	6.85%	-14.69%	-10.72%	6.22%	2.98%	87.27%	8.55%	6.49%	5.45%	-5.35%
ROIC Less NNEP Spread (ROIC-NNEP)	32.61%	15.54%	8.80%	18.37%	15.80%	22.94%	272.73%	-14.51%	-4.81%	14.42%	-114.62%
Return on Net Nonoperating Assets (RNNOA)	-8.34%	-5.90%	-2.66%	-6.37%	-6.37%	-6.24%	-57.41%	-2.33%	-2.26%	4.75%	-18.81%
Return on Equity (ROE)	-12.92%	0.95%	-17.35%	-17.10%	-0.16%	-3.26%	29.86%	6.22%	4.23%	10.20%	-24.16%
Cash Return on Invested Capital (CROIC)	-36.49%	-41.45%	-18.04%	-20.14%	-3.60%	-44.23%	45.42%	-72.66%	5.57%	8.74%	18.84%
Operating Return on Assets (OROA)	-2.28%	2.58%	-8.24%	-4.86%	2.28%	0.72%	4.67%	5.21%	0.11%	3.78%	-4.06%
Return on Assets (ROA)	-5.53%	0.52%	-9.74%	-8.36%	-0.07%	-1.45%	13.82%	2.51%	1.69%	5.15%	-12.73%
Return on Common Equity (ROCE)	-12.92%	0.95%	-17.35%	-17.10%	-0.16%	-3.26%	29.86%	6.22%	4.23%	10.20%	-24.16%
Return on Equity Simple (ROE_SIMPLE)	-8.01%	0.85%	-17.33%	-15.25%	-0.15%	-3.10%	23.48%	5.75%	4.11%	9.64%	-25.58%
Net Operating Profit after Tax (NOPAT)	-3.62	8.28	-22	-17	11	7.34	336	67	72	60	-51
NOPAT Margin	-1.83%	3.32%	-8.11%	-6.09%	3.30%	1.74%	78.15%	12.36%	5.38%	4.42%	-3.66%
Net Nonoperating Expense Percent (NNEP)	-37.19%	-8.68%	-23.49%	-29.10%	-9.59%	-19.96%	-185.46%	23.06%	11.30%	-8.97%	109.27%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	4.90%	4.28%	-3.77%
Cost of Revenue to Revenue	39.18%	28.85%	39.84%	30.67%	25.75%	25.35%	27.31%	25.90%	14.94%	13.68%	12.16%
SG&A Expenses to Revenue	53.96%	55.84%	55.22%	56.34%	52.56%	47.69%	45.04%	36.81%	19.08%	19.96%	20.98%
R&D to Revenue	9.48%	11.51%	16.53%	19.99%	16.51%	17.13%	13.83%	10.26%	6.36%	5.65%	5.82%
Operating Expenses to Revenue	63.44%	67.35%	71.75%	78.03%	69.53%	72.17%	61.90%	57.49%	79.53%	77.60%	113.49%
Earnings before Interest and Taxes (EBIT)	-5.65	9.22	-32	-25	15	5.50	49	87	2.01	62	-63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	9.01	25	-15	0.73	41	41	87	142	101	141	19
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	18.68	12.92	5.52	6.63	5.51	5.33	4.20	3.67	2.28	1.80	1.12
Price to Tangible Book Value (P/TBV)	21.75	15.06	7.01	8.26	6.82	12.52	6.14	0.00	24.84	7.01	2.47
Price to Revenue (P/Rev)	16.17	11.34	4.37	6.46	5.24	4.49	6.05	4.95	1.33	1.16	0.62
Price to Earnings (P/E)	0.00	1,520.80	0.00	0.00	0.00	0.00	17.86	63.85	0.00	167.68	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.07%	0.00%	0.00%	0.00%	0.00%	5.60%	1.57%	0.00%	0.60%	0.00%
Enterprise Value to Invested Capital (EV/IC)	34.01	18.36	7.38	10.23	8.70	6.05	5.26	2.77	1.89	1.65	1.11
Enterprise Value to Revenue (EV/Rev)	15.77	11.06	4.14	6.08	4.85	4.37	5.69	5.63	1.58	1.31	0.67
Enterprise Value to EBITDA (EV/EBITDA)	345.82	108.96	0.00	2,374.63	39.90	45.39	27.99	21.53	20.91	12.58	50.46
Enterprise Value to EBIT (EV/EBIT)	0.00	298.75	0.00	0.00	108.84	334.25	49.70	34.97	1,045.54	28.81	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	332.73	0.00	0.00	146.81	250.78	7.28	45.59	29.33	29.73	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	117.35	98.29	34.20	98.00	33.47	26.09	31.74	24.27	14.49	11.46	4.94
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	13.99	0.00	34.20	18.55	5.17
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.60	0.48	0.50	0.99	0.91	0.86	0.75	1.44	0.89	0.60	0.75
Long-Term Debt to Equity	0.00	0.00	0.50	0.99	0.90	0.86	0.51	0.92	0.85	0.59	0.49
Financial Leverage	-0.26	-0.38	-0.30	-0.35	-0.40	-0.27	-0.21	0.16	0.47	0.33	0.16
Leverage Ratio	2.33	1.83	1.78	2.05	2.19	2.25	2.16	2.48	2.50	1.98	1.90
Compound Leverage Factor	5.60	0.42	2.10	3.51	-0.06	-4.39	0.88	1.60	32.96	3.97	3.77
Debt to Total Capital	37.59%	32.27%	33.18%	49.73%	47.53%	46.30%	42.75%	58.96%	47.08%	37.52%	42.92%
Short-Term Debt to Total Capital	37.59%	32.27%	0.00%	0.06%	0.06%	0.00%	13.83%	21.05%	2.30%	0.62%	14.80%
Long-Term Debt to Total Capital	0.00%	0.00%	33.18%	49.67%	47.47%	46.30%	28.92%	37.90%	44.78%	36.90%	28.13%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	62.41%	67.73%	66.82%	50.27%	52.47%	53.70%	57.25%	41.04%	52.92%	62.48%	57.08%
Debt to EBITDA	11.44	4.12	-7.44	376.70	7.10	7.55	5.30	7.40	6.85	3.71	31.59
Net Debt to EBITDA	-8.82	-2.71	4.37	-148.56	-3.25	-1.25	-1.77	2.62	3.34	1.46	3.51
Long-Term Debt to EBITDA	0.00	0.00	-7.44	376.26	7.09	7.55	3.58	4.76	6.51	3.65	20.70
Debt to NOPAT	-28.52	12.57	-4.85	-15.84	26.11	41.72	1.38	15.68	9.60	8.76	-11.40
Net Debt to NOPAT	21.99	-8.26	2.85	6.25	-11.96	-6.91	-0.46	5.54	4.69	3.45	-1.27
Long-Term Debt to NOPAT	0.00	0.00	-4.85	-15.82	26.08	41.72	0.93	10.08	9.14	8.62	-7.47
Altman Z-Score	11.87	9.93	4.01	3.28	3.38	2.67	2.94	1.65	2.10	2.54	1.59
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.53	1.69	5.42	6.96	7.88	3.79	2.57	1.66	3.37	5.24	2.40
Quick Ratio	1.28	1.23	4.52	6.10	6.95	3.15	2.27	1.44	2.62	3.94	1.93
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-29	-50	-28	-33	-6.45	-109	175	-569	62	96	181
Operating Cash Flow to CapEx	115.58%	69.54%	135.39%	92.31%	336.71%	694.16%	203.78%	274.10%	483.02%	1,020.04%	1,780.64%
Free Cash Flow to Firm to Interest Expense	-3.48	-6.44	-3.90	-1.51	-0.29	-4.61	5.18	-17.92	1.54	1.76	117.91
Operating Cash Flow to Interest Expense	3.21	3.60	4.74	0.82	2.23	2.98	2.28	3.96	3.63	2.86	123.54
Operating Cash Flow Less CapEx to Interest Expense	0.43	-1.58	1.24	-0.07	1.57	2.55	1.16	2.52	2.88	2.58	116.60
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.80	0.70	0.71	0.56	0.51	0.55	0.41	0.32	0.71	0.83	0.90
Accounts Receivable Turnover	10.70	10.33	9.91	9.31	9.68	9.85	8.54	7.25	13.70	13.24	12.81
Inventory Turnover	3.46	1.58	2.37	2.42	1.93	2.00	1.91	1.72	2.05	1.84	1.48
Fixed Asset Turnover	3.63	3.30	2.89	2.76	3.13	3.95	3.56	3.33	7.17	7.55	8.22
Accounts Payable Turnover	15.76	9.27	13.55	7.93	5.98	7.86	10.10	13.37	15.47	11.95	9.79
Days Sales Outstanding (DSO)	34.12	35.34	36.84	39.22	37.69	37.07	42.72	50.34	26.65	27.57	28.49
Days Inventory Outstanding (DIO)	105.63	230.95	154.02	150.89	189.09	182.76	191.24	212.36	178.21	198.06	245.90
Days Payable Outstanding (DPO)	23.16	39.37	26.93	46.02	61.00	46.46	36.13	27.29	23.59	30.55	37.30
Cash Conversion Cycle (CCC)	116.59	226.92	163.93	144.09	165.78	173.37	197.83	235.40	181.27	195.08	237.09
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	92	150	155	170	188	304	465	1,101	1,111	1,076	843
Invested Capital Turnover	2.50	2.06	1.81	1.76	1.88	1.71	1.12	0.69	1.21	1.23	1.46
Increase / (Decrease) in Invested Capital	25	58	5.11	15	18	116	161	636	10	-36	-232
Enterprise Value (EV)	3,117	2,754	1,144	1,743	1,636	1,840	2,445	3,051	2,106	1,772	935
Market Capitalization	3,197	2,823	1,208	1,852	1,769	1,890	2,600	2,680	1,769	1,567	870
Book Value per Share	$4.75	$5.94	$5.85	$6.89	$7.81	$8.51	$14.26	$16.40	$17.03	$18.74	$16.86
Tangible Book Value per Share	$4.08	$5.10	$4.61	$5.53	$6.30	$3.62	$9.75	($0.87)	$1.56	$4.82	$7.63
Total Capital	274	322	328	556	612	661	1,082	1,780	1,464	1,393	1,364
Total Debt	103	104	109	276	291	306	463	1,049	689	522	585
Total Long-Term Debt	0.00	0.00	109	276	291	306	313	675	656	514	384
Net Debt	-79	-68	-64	-109	-133	-51	-154	371	336	205	65
Capital Expenditures (CapEx)	23	40	25	19	15	10	38	46	30	15	11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	19	48	26	24	34	8.93	26	63	96	143	152
Debt-free Net Working Capital (DFNWC)	177	207	198	335	418	301	548	720	384	421	637
Net Working Capital (NWC)	74	103	198	335	417	301	398	345	351	413	435
Net Nonoperating Expense (NNE)	10	6.42	16	25	12	18	190	25	40	-24	148
Net Nonoperating Obligations (NNO)	-79	-68	-64	-109	-133	-51	-154	371	336	205	65
Total Depreciation and Amortization (D&A)	15	16	17	26	26	35	38	54	99	79	82
Debt-free, Cash-free Net Working Capital to Revenue	9.70%	19.22%	9.28%	8.33%	10.14%	2.12%	6.12%	11.67%	7.17%	10.57%	10.87%
Debt-free Net Working Capital to Revenue	89.72%	83.07%	71.73%	116.95%	123.83%	71.46%	127.53%	132.89%	28.81%	31.20%	45.44%
Net Working Capital to Revenue	37.56%	41.28%	71.73%	116.84%	123.73%	71.46%	92.70%	63.70%	26.29%	30.56%	31.04%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.39)	$0.05	($1.02)	($1.07)	($0.01)	($0.27)	$3.41	$0.95	$0.35	$0.91	($2.15)
Adjusted Weighted Average Basic Shares Outstanding	36.24M	36.54M	37.24M	39.81M	41.23M	42.03M	42.67M	44.26M	45.52M	46.22M	46.25M
Adjusted Diluted Earnings per Share	($0.39)	$0.04	($1.02)	($1.07)	($0.01)	($0.27)	$3.33	$0.92	$0.34	$0.89	($2.15)
Adjusted Weighted Average Diluted Shares Outstanding	36.24M	41.30M	37.24M	39.81M	41.23M	42.03M	43.68M	45.63M	46.54M	51.98M	46.25M
Adjusted Basic & Diluted Earnings per Share	($0.39)	$0.00	$0.00	$0.00	($0.01)	($0.27)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	35.30M	37.05M	37.53M	40.71M	40.91M	41.51M	43.86M	44.85M	45.95M	46.50M	46.28M
Normalized Net Operating Profit after Tax (NOPAT)	-3.62	8.28	-22	-14	12	25	36	67	42	60	177
Normalized NOPAT Margin	-1.83%	3.32%	-8.11%	-4.90%	3.63%	5.94%	8.39%	12.36%	3.15%	4.42%	12.64%
Pre Tax Income Margin	-6.85%	0.85%	-13.69%	-14.82%	-0.13%	-2.55%	4.68%	10.42%	1.99%	9.14%	-9.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.68	1.19	-4.55	-1.14	0.68	0.23	1.46	2.75	0.05	1.14	-41.41
NOPAT to Interest Expense	-0.44	1.06	-3.17	-0.80	0.51	0.31	9.95	2.11	1.80	1.10	-33.50
EBIT Less CapEx to Interest Expense	-3.46	-4.00	-8.05	-2.02	0.02	-0.20	0.34	1.30	-0.70	0.86	-48.35
NOPAT Less CapEx to Interest Expense	-3.21	-4.12	-6.67	-1.69	-0.15	-0.12	8.83	0.66	1.04	0.82	-40.44
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10.83%	3.69%	1.39%	-17.25%

This table displays calculated financial ratios and metrics derived from Pacira BioSciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	1.49%	0.03%	-2.11%	2.08%	4.23%	5.05%	2.83%	3.74%
EBITDA Growth	-25.53%	0.00%	-53.78%	11.97%	12.16%	212.17%	77.68%	-19.42%	-425.28%	111.97%
EBIT Growth	-65.94%	0.00%	-117.96%	29.49%	61.81%	113.64%	520.93%	-28.80%	-907.27%	352.93%
NOPAT Growth	-131.13%	0.00%	-113.29%	-3.80%	262.55%	435.42%	501.96%	-46.28%	-942.66%	-25.55%
Net Income Growth	0.00%	0.00%	-386.12%	29.62%	1,666.81%	1,050.77%	145.96%	-26.69%	-1,421.29%	-224.98%
EPS Growth	0.00%	0.00%	-386.67%	27.50%	1,250.00%	405.26%	144.19%	-23.53%	-1,452.17%	-34.48%
Operating Cash Flow Growth	-29.25%	0.00%	-37.85%	45.94%	4.18%	13.20%	156.70%	22.38%	21.34%	-30.37%
Free Cash Flow Firm Growth	2,761.92%	97.31%	100.53%	113.63%	-314.97%	445.23%	2,839.88%	7.20%	113.16%	321.65%
Invested Capital Growth	-100.00%	0.93%	-0.48%	-4.90%	0.00%	-3.23%	-7.85%	-6.84%	-22.02%	-21.58%
Revenue Q/Q Growth	-1.15%	400.86%	-6.75%	5.69%	-3.27%	422.32%	-7.79%	6.53%	-5.31%	426.90%
EBITDA Q/Q Growth	-38.74%	-173.83%	-20.34%	227.84%	-38.63%	-26.17%	-39.13%	48.68%	-347.72%	148.11%
EBIT Q/Q Growth	-65.05%	-628.80%	68.40%	1,377.27%	-56.32%	-55.44%	-61.25%	116.05%	-595.19%	125.00%
NOPAT Q/Q Growth	-125.28%	2.88%	68.76%	1,354.33%	-57.29%	100.41%	-64.45%	67.62%	-769.95%	117.71%
Net Income Q/Q Growth	-103.49%	937.95%	-93.39%	231.87%	-57.85%	515.44%	-63.90%	110.34%	-859.64%	41.78%
EPS Q/Q Growth	-105.00%	-850.00%	-126.32%	218.60%	-54.90%	152.17%	-67.24%	105.26%	-897.44%	112.22%
Operating Cash Flow Q/Q Growth	43.11%	-1.45%	-54.50%	127.41%	2.16%	7.08%	3.19%	8.42%	1.28%	-38.55%
Free Cash Flow Firm Q/Q Growth	181.10%	-103.43%	119.49%	2,414.11%	-1,379.05%	105.51%	62.57%	-8.33%	57.03%	76.48%
Invested Capital Q/Q Growth	-100.00%	0.00%	2.53%	-3.18%	-1.62%	-0.91%	-2.37%	-2.11%	-17.65%	-0.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.74%	92.62%	69.43%	71.55%	75.75%	94.43%	71.63%	75.14%	76.95%	95.51%
EBITDA Margin	19.40%	-2.86%	11.30%	35.04%	22.23%	3.14%	19.26%	26.88%	-70.32%	6.42%
Operating Margin	12.71%	-1.18%	-1.93%	23.53%	10.81%	3.87%	7.91%	15.86%	-82.77%	2.78%
EBIT Margin	6.38%	-6.74%	-1.93%	23.37%	10.55%	0.90%	7.81%	15.84%	-82.84%	3.93%
Profit (Net Income) Margin	-0.41%	0.69%	-12.18%	15.20%	6.62%	7.80%	5.37%	10.61%	-85.11%	-9.40%
Tax Burden Percent	-33.49%	-121.84%	73.79%	68.06%	65.41%	70.03%	65.83%	51.62%	103.32%	222.24%
Interest Burden Percent	19.35%	8.43%	853.72%	95.57%	95.97%	1,237.79%	104.50%	129.73%	99.43%	-107.63%
Effective Tax Rate	133.49%	0.00%	0.00%	31.94%	34.59%	29.97%	34.17%	48.38%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-1.00%	-0.79%	9.47%	8.67%	3.35%	3.24%	5.31%	-41.69%	2.84%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	2.61%	-5.10%	9.08%	8.10%	19.44%	3.35%	7.25%	-67.81%	-71.71%
Return on Net Nonoperating Assets (RNNOA)	0.00%	1.22%	-2.78%	4.05%	2.47%	6.40%	1.07%	1.91%	-15.04%	-11.76%
Return on Equity (ROE)	0.00%	0.23%	-3.57%	13.52%	11.14%	9.75%	4.31%	7.21%	-56.72%	-8.92%
Cash Return on Invested Capital (CROIC)	200.00%	5.57%	2.90%	8.00%	-194.21%	8.74%	14.75%	12.56%	20.04%	18.84%
Operating Return on Assets (OROA)	0.00%	-4.79%	-0.76%	9.55%	9.16%	0.75%	3.43%	6.86%	-37.68%	3.52%
Return on Assets (ROA)	0.00%	0.49%	-4.78%	6.21%	5.75%	6.47%	2.36%	4.59%	-38.71%	-8.43%
Return on Common Equity (ROCE)	0.00%	0.23%	-3.57%	13.52%	11.14%	9.75%	4.31%	7.21%	-56.72%	-8.92%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	-1.36%	-0.57%	0.84%	0.00%	7.90%	7.23%	-12.10%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.13	-6.93	-2.16	27	12	23	8.70	15	-98	17
NOPAT Margin	-4.26%	-0.83%	-1.35%	16.01%	7.07%	2.71%	5.20%	8.19%	-57.94%	1.95%
Net Nonoperating Expense Percent (NNEP)	6.07%	-3.60%	4.31%	0.39%	0.58%	-16.09%	-0.11%	-1.94%	26.12%	74.55%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.47%	-	-	-	1.67%	-	-	-	1.27%
Cost of Revenue to Revenue	30.26%	7.38%	30.57%	28.45%	24.25%	5.57%	28.37%	24.86%	23.05%	4.49%
SG&A Expenses to Revenue	36.59%	7.63%	44.18%	38.27%	41.45%	7.69%	43.10%	38.27%	44.10%	8.96%
R&D to Revenue	11.59%	2.09%	10.69%	11.11%	12.71%	2.27%	10.91%	11.42%	11.33%	2.69%
Operating Expenses to Revenue	57.03%	92.17%	71.36%	48.02%	64.94%	87.05%	63.72%	59.27%	159.71%	124.95%
Earnings before Interest and Taxes (EBIT)	11	-57	-3.10	40	17	7.71	13	28	-140	35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	32	-24	18	59	36	27	32	48	-119	57
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.28	2.44	2.28	1.71	1.80	1.52	1.51	0.93	1.12
Price to Tangible Book Value (P/TBV)	0.00	24.84	23.87	13.87	8.34	7.01	5.23	5.09	2.24	2.47
Price to Revenue (P/Rev)	0.00	1.33	2.80	2.75	2.14	1.16	1.99	1.93	1.00	0.62
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	203.93	167.68	19.28	20.94	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.49%	0.60%	5.19%	4.78%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	1.89	1.97	1.94	1.55	1.65	1.44	1.44	0.93	1.11
Enterprise Value to Revenue (EV/Rev)	0.00	1.58	3.36	3.19	2.52	1.31	2.22	2.14	1.14	0.67
Enterprise Value to EBITDA (EV/EBITDA)	0.00	20.91	17.78	16.11	12.28	12.58	8.38	8.74	55.02	50.46
Enterprise Value to EBIT (EV/EBIT)	0.00	1,045.54	79.21	57.19	38.14	28.81	14.63	16.05	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	29.33	81.18	63.39	53.39	29.73	21.07	25.35	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	14.49	16.81	14.51	11.25	11.46	8.21	7.62	3.88	4.94
Enterprise Value to Free Cash Flow (EV/FCFF)	4.81	34.20	67.71	23.61	0.00	18.55	9.39	11.06	4.09	5.17
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.89	0.72	0.68	0.63	0.60	0.58	0.67	0.78	0.75
Long-Term Debt to Equity	0.00	0.85	0.71	0.66	0.62	0.59	0.57	0.67	0.51	0.49
Financial Leverage	-0.30	0.47	0.55	0.45	0.31	0.33	0.32	0.26	0.22	0.16
Leverage Ratio	1.89	2.50	2.31	2.09	1.85	1.98	1.87	1.89	1.93	1.90
Compound Leverage Factor	0.37	0.21	19.73	2.00	1.77	24.49	1.96	2.45	1.92	-2.04
Debt to Total Capital	0.00%	47.08%	41.89%	40.58%	38.68%	37.52%	36.84%	40.13%	43.93%	42.92%
Short-Term Debt to Total Capital	0.00%	2.30%	0.82%	1.43%	0.64%	0.62%	0.61%	0.00%	15.07%	14.80%
Long-Term Debt to Total Capital	0.00%	44.78%	41.07%	39.14%	38.05%	36.90%	36.23%	40.13%	28.86%	28.13%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	52.92%	58.11%	59.42%	61.32%	62.48%	63.16%	59.87%	56.07%	57.08%
Debt to EBITDA	0.00	6.85	4.38	4.16	3.84	3.71	2.88	3.48	40.85	31.59
Net Debt to EBITDA	0.00	3.34	2.94	2.23	1.86	1.46	0.87	0.88	6.73	3.51
Long-Term Debt to EBITDA	0.00	6.51	4.30	4.01	3.78	3.65	2.83	3.48	26.84	20.70
Debt to NOPAT	0.00	9.60	20.01	16.36	16.69	8.76	7.23	10.09	-12.93	-11.40
Net Debt to NOPAT	0.00	4.69	13.42	8.76	8.08	3.45	2.19	2.54	-2.13	-1.27
Long-Term Debt to NOPAT	0.00	9.14	19.62	15.78	16.42	8.62	7.11	10.09	-8.49	-7.47
Altman Z-Score	0.00	1.98	1.99	2.14	1.84	2.43	1.89	1.84	0.79	1.80
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	3.37	3.81	3.94	4.78	5.24	5.81	6.82	2.25	2.40
Quick Ratio	0.00	2.62	2.71	2.94	3.55	3.94	4.58	5.49	1.81	1.93
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	500	-17	3.34	84	-1,074	59	98	90	141	249
Operating Cash Flow to CapEx	823.28%	765.42%	291.36%	1,277.88%	1,309.31%	2,646.50%	1,731.35%	3,348.18%	1,317.69%	1,564.31%
Free Cash Flow to Firm to Interest Expense	50.68	-1.55	0.13	21.72	-309.99	2.91	29.61	0.00	30.14	0.00
Operating Cash Flow to Interest Expense	4.33	3.81	0.72	11.25	12.83	2.34	14.81	0.00	11.50	0.00
Operating Cash Flow Less CapEx to Interest Expense	3.80	3.31	0.47	10.37	11.85	2.25	13.95	0.00	10.63	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.71	0.39	0.41	0.87	0.83	0.44	0.43	0.45	0.90
Accounts Receivable Turnover	0.00	13.70	7.22	7.04	0.00	13.24	7.00	6.77	7.03	12.81
Inventory Turnover	0.00	2.05	2.16	2.18	0.00	1.84	1.93	1.83	1.71	1.48
Fixed Asset Turnover	0.00	7.17	3.60	3.60	0.00	7.55	3.86	3.95	4.06	8.22
Accounts Payable Turnover	0.00	15.47	13.22	10.99	0.00	11.95	13.95	8.34	9.94	9.79
Days Sales Outstanding (DSO)	0.00	26.65	50.54	51.86	0.00	27.57	52.16	53.89	51.89	28.49
Days Inventory Outstanding (DIO)	0.00	178.21	169.08	167.62	0.00	198.06	189.17	199.26	213.37	245.90
Days Payable Outstanding (DPO)	0.00	23.59	27.61	33.22	0.00	30.55	26.16	43.75	36.74	37.30
Cash Conversion Cycle (CCC)	0.00	181.27	192.02	186.27	0.00	195.08	215.17	209.41	228.53	237.09
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	1,111	1,140	1,103	1,085	1,076	1,050	1,028	846	843
Invested Capital Turnover	0.00	1.21	0.59	0.59	1.23	1.23	0.62	0.65	0.72	1.46
Increase / (Decrease) in Invested Capital	-507	10	-5.50	-57	1,085	-36	-89	-75	-239	-232
Enterprise Value (EV)	2,437	2,106	2,247	2,138	1,678	1,772	1,517	1,480	791	935
Market Capitalization	2,437	1,769	1,875	1,843	1,424	1,567	1,359	1,332	694	870
Book Value per Share	$0.00	$17.03	$16.71	$17.57	$17.91	$18.74	$19.19	$18.89	$16.25	$16.86
Tangible Book Value per Share	$0.00	$1.56	$1.71	$2.89	$3.68	$4.82	$5.59	$5.62	$6.71	$7.63
Total Capital	0.00	1,464	1,322	1,360	1,356	1,393	1,412	1,469	1,337	1,364
Total Debt	0.00	689	554	552	525	522	520	589	587	585
Total Long-Term Debt	0.00	656	543	532	516	514	512	589	386	384
Net Debt	0.00	336	371	295	254	205	158	149	97	65
Capital Expenditures (CapEx)	5.18	5.49	6.57	3.40	3.39	1.80	2.84	1.59	4.09	2.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	96	114	119	127	143	132	135	131	152
Debt-free Net Working Capital (DFNWC)	0.00	384	288	340	362	421	458	540	585	637
Net Working Capital (NWC)	0.00	351	277	320	354	413	450	540	384	435
Net Nonoperating Expense (NNE)	-6.44	-13	17	1.38	0.73	-44	-0.28	-4.31	46	101
Net Nonoperating Obligations (NNO)	0.00	336	371	295	254	205	158	149	97	65
Total Depreciation and Amortization (D&A)	22	33	21	20	19	19	19	20	21	22
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	7.17%	17.08%	17.80%	19.09%	10.57%	19.42%	19.60%	18.88%	10.87%
Debt-free Net Working Capital to Revenue	0.00%	28.81%	43.08%	50.79%	54.42%	31.20%	67.23%	78.16%	84.18%	45.44%
Net Working Capital to Revenue	0.00%	26.29%	41.46%	47.88%	53.12%	30.56%	65.96%	78.16%	55.19%	31.04%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.22)	($0.43)	$0.56	$0.23	$0.55	$0.19	$0.41	($3.11)	$0.36
Adjusted Weighted Average Basic Shares Outstanding	0.00	45.52M	45.95M	46.09M	46.42M	46.22M	46.50M	46.17M	46.13M	46.25M
Adjusted Diluted Earnings per Share	$0.00	($0.19)	($0.43)	$0.51	$0.23	$0.58	$0.19	$0.39	($3.11)	$0.38
Adjusted Weighted Average Diluted Shares Outstanding	0.00	46.54M	45.95M	52.05M	52.07M	51.98M	52.19M	50.54M	46.13M	46.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	45.95M	45.99M	46.42M	46.44M	46.50M	46.55M	46.13M	46.17M	46.28M
Normalized Net Operating Profit after Tax (NOPAT)	15	-6.93	6.31	16	14	23	9.95	16	15	17
Normalized NOPAT Margin	9.10%	-0.83%	3.94%	9.34%	8.41%	2.71%	5.95%	8.98%	9.11%	1.95%
Pre Tax Income Margin	1.24%	-0.57%	-16.51%	22.34%	10.13%	11.14%	8.16%	20.55%	-82.37%	-4.23%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.08	-5.12	-0.12	10.25	4.99	0.38	3.94	0.00	-29.78	0.00
NOPAT to Interest Expense	-0.72	-0.63	-0.08	7.02	3.35	1.14	2.62	0.00	-20.83	0.00
EBIT Less CapEx to Interest Expense	0.56	-5.62	-0.36	9.37	4.01	0.29	3.08	0.00	-30.65	0.00
NOPAT Less CapEx to Interest Expense	-1.25	-1.12	-0.33	6.14	2.37	1.05	1.77	0.00	-21.70	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	3.69%	-22.36%	-51.18%	33.48%	1.39%	0.00%	54.02%	-37.86%	-17.25%

Frequently Asked Questions About Pacira BioSciences' Financials

When does Pacira BioSciences's fiscal year end?

According to the most recent income statement we have on file, Pacira BioSciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Pacira BioSciences' net income changed over the last 10 years?

Pacira BioSciences' net income appears to be on a downward trend, with a most recent value of -$199.12 million in 2024, rising from -$13.72 million in 2014. The previous period was $83.91 million in 2023.

What is Pacira BioSciences's operating income?

Pacira BioSciences's total operating income in 2024 was -$73.37 million, based on the following breakdown:

Total Gross Profit: $1.23 billion
Total Operating Expenses: $1.59 billion

How has Pacira BioSciences revenue changed over the last 10 years?

Over the last 10 years, Pacira BioSciences' total revenue changed from $197.67 million in 2014 to $1.40 billion in 2024, a change of 609.2%.

How much debt does Pacira BioSciences have?

Pacira BioSciences' total liabilities were at $775.17 million at the end of 2024, a 10.1% increase from 2023, and a 400.3% increase since 2014.

How much cash does Pacira BioSciences have?

In the past 10 years, Pacira BioSciences' cash and equivalents has ranged from $35.94 million in 2016 to $585.58 million in 2021, and is currently $276.77 million as of their latest financial filing in 2024.

How has Pacira BioSciences' book value per share changed over the last 10 years?

Over the last 10 years, Pacira BioSciences' book value per share changed from 4.75 in 2014 to 16.86 in 2024, a change of 255.1%.

Remove Ads

Related Companies

This page (NASDAQ:PCRX) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacira BioSciences (PCRX) Financials

Frequently Asked Questions About Pacira BioSciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacira BioSciences (PCRX) Financials

Annual Income Statements for Pacira BioSciences

Quarterly Income Statements for Pacira BioSciences

Annual Cash Flow Statements for Pacira BioSciences

Quarterly Cash Flow Statements for Pacira BioSciences

Annual Balance Sheets for Pacira BioSciences

Quarterly Balance Sheets for Pacira BioSciences

Annual Metrics and Ratios for Pacira BioSciences

Quarterly Metrics and Ratios for Pacira BioSciences

Frequently Asked Questions About Pacira BioSciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools